MOLLY L PARKER

Allopathic & Osteopathic Physicians|Family Medicine JONESVILLE, MI NPI 1992074231

General Payments — all program years on this page

$19,147.48

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 98
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $8,342.30 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $6,720.001
Travel and Lodging $1,385.185
Food and Beverage $237.1211

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $8,209.8110
ABBVIE INC. $63.943
Novo Nordisk AS $54.543
Lilly USA, LLC $14.011

By program year

Program yearAmountRecords
2018 $81.965
2019 $12.601
2020 $70.815
2021 $1,466.3236
2022 $2,166.1120
2023 $7,007.3814
2024 $8,342.3017

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097318402 Novo Nordisk Inc $21.24 04/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097621209 Novo Nordisk Inc $20.19 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097836929 Novo Nordisk Inc $13.11 05/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105184598 ABBVIE INC. $20.97 01/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105184600 ABBVIE INC. $28.60 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105184602 ABBVIE INC. $14.37 05/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118263455 Boehringer Ingelheim Pharmaceuticals, Inc. $9.33 02/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118263457 Boehringer Ingelheim Pharmaceuticals, Inc. $25.84 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118263459 Boehringer Ingelheim Pharmaceuticals, Inc. $34.46 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118263461 Boehringer Ingelheim Pharmaceuticals, Inc. $35.00 12/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118263463 Boehringer Ingelheim Pharmaceuticals, Inc. $132.67 10/23/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1118263465 Boehringer Ingelheim Pharmaceuticals, Inc. $132.67 10/30/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1118263467 Boehringer Ingelheim Pharmaceuticals, Inc. $140.00 12/02/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1118263469 Boehringer Ingelheim Pharmaceuticals, Inc. $395.24 09/20/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1118263471 Boehringer Ingelheim Pharmaceuticals, Inc. $584.60 10/23/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1118263473 Boehringer Ingelheim Pharmaceuticals, Inc. $6,720.00 12/02/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1135218251 Lilly USA, LLC $14.01 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.